Analysis
2020
Racine
Analysis
2020
Exploration
Accueil
Racine
Racine

Serveur d'exploration Stress et Covid

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Prostate Cancer Radiotherapy Recommendations in Response to COVID-19

Identifieur interne : 000248 ( 2020/Analysis ); précédent : 000247; suivant : 000249

Prostate Cancer Radiotherapy Recommendations in Response to COVID-19

Auteurs : Nicholas G. Zaorsky

Source :

RBID : PMC:7118610

Abstract

Purpose

During a global pandemic the benefit of routine visits and treatment of cancer patients must be weighed against the risks to patients, staff, and society. Prostate cancer is one of the most common cancers Radiation Oncology departments treat, and efficient resource utilization is essential in the setting of a pandemic. Herein, we aim to establish recommendations and a framework by which to evaluate prostate radiotherapy management decisions.

Patients and Methods

Radiation Oncologists from the United States and United Kingdom rapidly conducted a systematic review and agreed upon recommendations to safely manage prostate cancer patients during the COVID-19 pandemic. A RADS framework was created: Remote visits, and Avoidance, Deferment, and Shortening of radiotherapy was applied to determine appropriate approaches.

Results

Recommendations are provided by National Comprehensive Cancer Network (NCCN) risk group, including clinical node positive, post-prostatectomy, oligometastatic, and low volume M1 disease. Across all prostate cancer stages, telemedicine consultations and return visits were recommended when resources/staff available. Delays in consultations and return visits was deemed safe based on stage of disease between 1-6 months. Treatment can be avoided or delayed until safe for very low, low, and favorable intermediate-risk disease. Unfavorable intermediate-risk, high-risk, clinical node positive, recurrence post-surgery, oligometastatic, and low-volume M1 disease can receive neoadjuvant hormone therapy for 4-6 months as necessary. Ultrahypofractionation was preferred for localized, oligometastatic, and low volume M1, and moderate hypofractionation was preferred for post-prostatectomy and clinical node positive disease. Salvage was preferred to adjuvant radiation.

Conclusion

Resources can be reduced for all identified stages of prostate cancer. The RADS (Remote visits, and Avoidance, Deferment, and Shortening of radiotherapy) framework can be applied to other disease sites to help with decision making in a global pandemic.


Url:
DOI: 10.1016/j.adro.2020.03.010
PubMed: NONE
PubMed Central: 7118610


Affiliations:

Links toward previous steps (curation, corpus...)

Links to Exploration step

PMC:7118610

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Prostate Cancer Radiotherapy Recommendations in Response to COVID-19</title>
<author>
<name sortKey="Zaorsky, Nicholas G" sort="Zaorsky, Nicholas G" uniqKey="Zaorsky N" first="Nicholas G." last="Zaorsky">Nicholas G. Zaorsky</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PMC</idno>
<idno type="pmc">7118610</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7118610</idno>
<idno type="RBID">PMC:7118610</idno>
<idno type="doi">10.1016/j.adro.2020.03.010</idno>
<idno type="pmid">NONE</idno>
<date when="2020">2020</date>
<idno type="wicri:Area/Pmc/Corpus">000594</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000594</idno>
<idno type="wicri:Area/Pmc/Curation">000594</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000594</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000201</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000201</idno>
<idno type="wicri:Area/Ncbi/Merge">001407</idno>
<idno type="wicri:Area/Ncbi/Curation">001407</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001407</idno>
<idno type="wicri:Area/Main/Merge">000248</idno>
<idno type="wicri:Area/Main/Curation">000248</idno>
<idno type="wicri:Area/Main/Exploration">000248</idno>
<idno type="wicri:Area/2020/Extraction">000248</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a" type="main">Prostate Cancer Radiotherapy Recommendations in Response to COVID-19</title>
<author>
<name sortKey="Zaorsky, Nicholas G" sort="Zaorsky, Nicholas G" uniqKey="Zaorsky N" first="Nicholas G." last="Zaorsky">Nicholas G. Zaorsky</name>
</author>
</analytic>
<series>
<title level="j">Advances in Radiation Oncology</title>
<idno type="eISSN">2452-1094</idno>
<imprint>
<date when="2020">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass></textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">
<sec>
<title>Purpose</title>
<p>During a global pandemic the benefit of routine visits and treatment of cancer patients must be weighed against the risks to patients, staff, and society. Prostate cancer is one of the most common cancers Radiation Oncology departments treat, and efficient resource utilization is essential in the setting of a pandemic. Herein, we aim to establish recommendations and a framework by which to evaluate prostate radiotherapy management decisions.</p>
</sec>
<sec>
<title>Patients and Methods</title>
<p>Radiation Oncologists from the United States and United Kingdom rapidly conducted a systematic review and agreed upon recommendations to safely manage prostate cancer patients during the COVID-19 pandemic. A RADS framework was created: Remote visits, and Avoidance, Deferment, and Shortening of radiotherapy was applied to determine appropriate approaches.</p>
</sec>
<sec>
<title>Results</title>
<p>Recommendations are provided by National Comprehensive Cancer Network (NCCN) risk group, including clinical node positive, post-prostatectomy, oligometastatic, and low volume M1 disease. Across all prostate cancer stages, telemedicine consultations and return visits were recommended when resources/staff available. Delays in consultations and return visits was deemed safe based on stage of disease between 1-6 months. Treatment can be avoided or delayed until safe for very low, low, and favorable intermediate-risk disease. Unfavorable intermediate-risk, high-risk, clinical node positive, recurrence post-surgery, oligometastatic, and low-volume M1 disease can receive neoadjuvant hormone therapy for 4-6 months as necessary. Ultrahypofractionation was preferred for localized, oligometastatic, and low volume M1, and moderate hypofractionation was preferred for post-prostatectomy and clinical node positive disease. Salvage was preferred to adjuvant radiation.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>Resources can be reduced for all identified stages of prostate cancer. The RADS (Remote visits, and Avoidance, Deferment, and Shortening of radiotherapy) framework can be applied to other disease sites to help with decision making in a global pandemic.</p>
</sec>
</div>
</front>
<back>
<div1 type="bibliography">
<listBibl>
<biblStruct>
<analytic>
<author>
<name sortKey="Liang, W" uniqKey="Liang W">W. Liang</name>
</author>
<author>
<name sortKey="Guan, W" uniqKey="Guan W">W. Guan</name>
</author>
<author>
<name sortKey="Chen, R" uniqKey="Chen R">R. Chen</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Wu, Z" uniqKey="Wu Z">Z. Wu</name>
</author>
<author>
<name sortKey="Mcgoogan, J M" uniqKey="Mcgoogan J">J.M. McGoogan</name>
</author>
</analytic>
</biblStruct>
<biblStruct></biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Mohler, J L" uniqKey="Mohler J">J.L. Mohler</name>
</author>
<author>
<name sortKey="Antonarakis, E S" uniqKey="Antonarakis E">E.S. Antonarakis</name>
</author>
<author>
<name sortKey="Armstrong, A J" uniqKey="Armstrong A">A.J. Armstrong</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Van Doremalen, N" uniqKey="Van Doremalen N">N. van Doremalen</name>
</author>
<author>
<name sortKey="Bushmaker, T" uniqKey="Bushmaker T">T. Bushmaker</name>
</author>
<author>
<name sortKey="Morris, D H" uniqKey="Morris D">D.H. Morris</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Hamdy, F C" uniqKey="Hamdy F">F.C. Hamdy</name>
</author>
<author>
<name sortKey="Donovan, J L" uniqKey="Donovan J">J.L. Donovan</name>
</author>
<author>
<name sortKey="Lane, J" uniqKey="Lane J">J. Lane</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Klotz, L" uniqKey="Klotz L">L. Klotz</name>
</author>
<author>
<name sortKey="Vesprini, D" uniqKey="Vesprini D">D. Vesprini</name>
</author>
<author>
<name sortKey="Sethukavalan, P" uniqKey="Sethukavalan P">P. Sethukavalan</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Pisansky, T M" uniqKey="Pisansky T">T.M. Pisansky</name>
</author>
<author>
<name sortKey="Hunt, D" uniqKey="Hunt D">D. Hunt</name>
</author>
<author>
<name sortKey="Gomella, L G" uniqKey="Gomella L">L.G. Gomella</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Morris, W J" uniqKey="Morris W">W.J. Morris</name>
</author>
<author>
<name sortKey="Tyldesley, S" uniqKey="Tyldesley S">S. Tyldesley</name>
</author>
<author>
<name sortKey="Rodda, S" uniqKey="Rodda S">S. Rodda</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Zapatero, A" uniqKey="Zapatero A">A. Zapatero</name>
</author>
<author>
<name sortKey="Guerrero, A" uniqKey="Guerrero A">A. Guerrero</name>
</author>
<author>
<name sortKey="Maldonado, X" uniqKey="Maldonado X">X. Maldonado</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Spratt, D" uniqKey="Spratt D">D. Spratt</name>
</author>
<author>
<name sortKey="Dess, R" uniqKey="Dess R">R. Dess</name>
</author>
<author>
<name sortKey="Efstathiou, J" uniqKey="Efstathiou J">J. Efstathiou</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Iversen, P" uniqKey="Iversen P">P. Iversen</name>
</author>
<author>
<name sortKey="Johansson, J E" uniqKey="Johansson J">J.-E. Johansson</name>
</author>
<author>
<name sortKey="Lodding, P" uniqKey="Lodding P">P. Lodding</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Kneebone, A" uniqKey="Kneebone A">A. Kneebone</name>
</author>
<author>
<name sortKey="Fraser Browne, C" uniqKey="Fraser Browne C">C. Fraser-Browne</name>
</author>
<author>
<name sortKey="Delprado, W" uniqKey="Delprado W">W. Delprado</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Brand, D H" uniqKey="Brand D">D.H. Brand</name>
</author>
<author>
<name sortKey="Tree, A C" uniqKey="Tree A">A.C. Tree</name>
</author>
<author>
<name sortKey="Ostler, P" uniqKey="Ostler P">P. Ostler</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Dearnaley, D" uniqKey="Dearnaley D">D. Dearnaley</name>
</author>
<author>
<name sortKey="Syndikus, I" uniqKey="Syndikus I">I. Syndikus</name>
</author>
<author>
<name sortKey="Mossop, H" uniqKey="Mossop H">H. Mossop</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Chin, S" uniqKey="Chin S">S. Chin</name>
</author>
<author>
<name sortKey="Fatimilehin, A" uniqKey="Fatimilehin A">A. Fatimilehin</name>
</author>
<author>
<name sortKey="Walshaw, R" uniqKey="Walshaw R">R. Walshaw</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Parker, C C" uniqKey="Parker C">C.C. Parker</name>
</author>
<author>
<name sortKey="James, N D" uniqKey="James N">N.D. James</name>
</author>
<author>
<name sortKey="Brawley, C D" uniqKey="Brawley C">C.D. Brawley</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Widmark, A" uniqKey="Widmark A">A. Widmark</name>
</author>
<author>
<name sortKey="Gunnlaugsson, A" uniqKey="Gunnlaugsson A">A. Gunnlaugsson</name>
</author>
<author>
<name sortKey="Beckman, L" uniqKey="Beckman L">L. Beckman</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Widmark, A" uniqKey="Widmark A">A. Widmark</name>
</author>
<author>
<name sortKey="Klepp, O" uniqKey="Klepp O">O. Klepp</name>
</author>
<author>
<name sortKey="Solberg, A" uniqKey="Solberg A">A. Solberg</name>
</author>
</analytic>
</biblStruct>
</listBibl>
</div1>
</back>
</TEI>
<affiliations>
<list></list>
<tree>
<noCountry>
<name sortKey="Zaorsky, Nicholas G" sort="Zaorsky, Nicholas G" uniqKey="Zaorsky N" first="Nicholas G." last="Zaorsky">Nicholas G. Zaorsky</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/2020/Analysis

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000248 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd -nk 000248 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    StressCovidV1
   |flux=    2020
   |étape=   Analysis
   |type=    RBID
   |clé=     PMC:7118610
   |texte=   Prostate Cancer Radiotherapy Recommendations in Response to COVID-19
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/RBID.i   -Sk "pubmed:NONE" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd   \
       | NlmPubMed2Wicri -a StressCovidV1
Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Wed May 6 16:44:09 2020. Site generation: Sun Mar 28 08:26:57 2021